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Abstract
Introduction:  High-frequency  audiometry  may  contribute  to  the  early  detection  of  hearing
loss caused  by  ototoxic  medications.  Many  ototoxic  drugs  are  widely  used  in  the  treatment
of patients  with  cystic  ﬁbrosis.  Early  detection  of  hearing  loss  should  allow  known  harmful
drugs to  be  identiﬁed  before  the  damage  affects  speech  frequencies.  The  damage  caused  by
ototoxicity is  irreversible,  resulting  in  important  social  and  psychological  consequences.  In  chil-
dren, hearing  loss,  even  when  restricted  to  high  frequencies,  can  affect  the  development  of
language.
Objective:  To  investigate  the  efﬁcacy  and  effectiveness  of  hearing  monitoring  through  high-
frequency  audiometry  in  pediatric  patients  with  cystic  ﬁbrosis.
Methods:  Electronic  databases  PubMed,  MEDLINE,  Web  of  Science  and  LILACS  were  searched,
from January  to  November  2015.  The  selected  studies  included  those  in  which  high-frequency
audiometry  was  performed  in  patients  with  cystic  ﬁbrosis,  undergoing  treatment  with  ototoxic
drugs and  published  in  Portuguese,  English  and  Spanish.  The  GRADE  system  was  chosen  for  the
evaluation  of  the  methodological  quality  of  the  articles.
Results:  During  the  search  process  carried  out  from  January  2015  to  November  2015,  512  pub-
lications  were  identiﬁed,  of  which  250  were  found  in  PubMed,  118  in  MedLine,  142  in  Web  of
Science and  2  in  LILACS.  Of  these,  nine  articles  were  selected. Please cite this article as: Caumo DT, Geyer LB, Teixeira AR, Barreto SS. Hearing thresholds at high frequency in patients with cystic
ﬁbrosis: a systematic review. Braz J Otorhinolaryngol. 2016. http://dx.doi.org/10.1016/j.bjorl.2016.10.006
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Conclusion:  The  incidence  of  hearing  loss  was  identiﬁed  at  high  frequencies  in  cystic  ﬁbrosis
patients  without  hearing  complaints.  It  is  assumed  that  high-frequency  audiometry  can  be  an
early diagnostic  method  to  be  recommended  for  hearing  investigation  of  patients  at  risk  of
ototoxicity.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published
by Elsevier  Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY  license  (http://
creativecommons.org/licenses/by/4.0/).
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Limiares  auditivos  em  altas  frequências  em  pacientes  com  ﬁbrose  cística:  revisão
sistemática
Resumo
Introduc¸ão:  A  audiometria  de  altas  frequências  pode  contribuir  para  a  detecc¸ão  precoce  de
alterac¸ões auditivas  causadas  por  medicac¸ões  ototóxicas.  No  tratamento  dos  pacientes  com
ﬁbrose cística,  existem  muitos  fármacos  ototóxicos  que  são  amplamente  utilizados.  A  detecc¸ão
precoce de  alterac¸ões  auditivas  deve  permitir  que  estas  sejam  identiﬁcadas  antes  que  o  dano
atinja as  frequências  da  fala.  A  lesão  causada  pela  ototoxicidade  é  irreversível,  trazendo  impor-
tantes consequências  sociais  e  psicológicas.  Nas  crianc¸as,  a  perda  auditiva,  mesmo  restrita  às
altas frequências,  pode  afetar  o  desenvolvimento  da  linguagem.
Objetivo:  Investigar  a  eﬁcácia  e  a  efetividade  do  monitoramento  da  audic¸ão  por  meio  da
audiometria  de  altas  frequências  em  pacientes  pediátricos  com  ﬁbrose  cística.
Método: Foram  consultadas  as  bases  de  dados  eletrônicas  PubMed,  MEDLINE,  Web  of  Science
e LILACS,  de  janeiro  à  novembro  de  2015.  Foram  selecionados  os  estudos  em  que  foi  realizada
audiometria  de  altas  frequências  em  pacientes  com  ﬁbrose  cística  em  tratamento  com  medica-
mentos ototóxicos,  e  publicados  em  português,  inglês  e  espanhol.  Para  a  avaliac¸ão  da  qualidade
metodológica  dos  artigos  optou-se  pela  utilizac¸ão  do  Sistema  GRADE.
Resultados:  No  processo  de  busca  realizado  de  Janeiro  de  2015  à  Novembro  de  2015  foram
encontradas  512  publicac¸ões,  sendo  250  na  PubMed,  118  na  MedLine,  142  na  Web  Of  Science  e
dois na  LILACS.  Desses,  foram  selecionados  nove  artigos.
Conclusão:  Identiﬁcou-se  a  ocorrência  de  perda  auditiva  em  altas  frequências,  em  pacientes
com ﬁbrose  cística  sem  queixas  auditivas.  Admite-se  que  audiometria  em  altas  frequências
possa ser  um  método  de  diagnóstico  precoce  a  ser  recomendado  para  investigac¸ão  auditiva  de
pacientes  em  risco  de  ototoxicidade.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY  (http://
creativecommons.org/licenses/by/4.0/).
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ystic  ﬁbrosis  (CF),  also  called  mucoviscidosis,  is  caused  by
utations  in  a  gene  located  on  the  long  arm  of  chromosome
 (7q31).  This  gene  encodes  the  cystic  ﬁbrosis  transmem-
rane  conductance  regulator  (CFTR),  which  functions  as  a
hloride  channel,  performing  and  controlling  ion  transporta-
ion  through  the  cell  membrane.1
Individuals  with  CF  have  chloride  secretion  failure  in  the
espiratory  epithelium,  which  results  in  excessive  sodium
bsorption,  resulting  in  increased  inﬂux  of  water  into  cells
nd  therefore  elevating  mucus  viscosity.  The  mucus  becomes
pproximately  30--60  times  thicker  than  normal.  It  does
ot  directly  affect  ciliary  beat,  but  ciliary  action  becomes
neffective  in  the  clearance  of  such  highly  viscous  sub-
tance,  causing  stasis,  predisposing  to  ostial  obstruction
nd  increased  bacterial  colonization.2,3 This  can  lead  to
ecurrent  pulmonary  infections,  chronic  obstructive  pul-
onary  disease,  sinusitis,  nasal  polyps,  gastrointestinal
u
w
calabsorption  secondary  to  pancreatic  failure,  meconium
leus,  rectal  prolapse  and  infertility  due  to  obstruction  of
he  vas  deferens.2
The  incidence  of  CF  varies  according  to  ethnicity,  occur-
ing  more  commonly  in  Caucasians.  Being  an  autosomal
ecessive  disease,  when  each  parent  has  the  gene  for  CF,
he  probability  of  the  birth  of  a  child  with  the  disease  is
5%.  In  accessing  ethnic  groups,  the  incidence  of  CF  varies
rom  1/2000  to  1/5000  live  births  among  Caucasians  in
urope,  the  United  States  and  Canada,  1/15,000  in  African-
mericans,  and  1/40,000  in  Finland.4,5
In  Brazil,  the  estimated  incidence  for  the  southern  region
s  closer  to  that  of  the  Central  European  Caucasian  pop-
lation,  whereas  for  the  other  regions,  it  decreases  to
pproximately  1/10,000  live  births.4 The  prevalence  of  the
utation  in  the  CFTR  gene  (F508),  in  the  pediatric  pop-
lation  of  patients  with  CF  born  in  Porto  Alegre  is  60%,
ith  an  estimated  incidence  of  10  cases  a  year  in  the
ity.6
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Hearing  thresholds  at  high  frequency  in  patients  with  cystic
The  diagnosis  of  CF  is  essentially  clinical,  although  neona-
tal  screening  has  allowed  the  diagnosis  of  cases  even  before
symptom  onset.  The  diagnosis  can  be  made  through  the  iden-
tiﬁcation  of  two  mutations  in  the  CF  gene,  two  abnormal
results  of  the  sweat  test,  or  the  presence  of  at  least  one  of
the  following  symptoms:  obstructive/suppurative  lung  dis-
ease  or  chronic  sinus  disease,  chronic  exocrine  pancreatic
failure  or  family  history  of  CF.2,4 For  patients  in  whom  the
chloride  concentration  in  sweat  is  normal  or  borderline  and
in  which  mutations  in  the  two  CF  genes  are  not  identiﬁed,
the  nasal  potential  difference  (NPD)  measurement  can  be
used  as  evidence  of  CFTR  dysfunction.  Clinical  decision-
making  will  continue  to  be  essential  for  patients  that  have
‘‘atypical’’  or  typical  symptoms,  but  have  no  conclusive  evi-
dence  of  CFTR  dysfunction.7
When  treating  patients  with  CF,  many  ototoxic  drugs  are
widely  used,  including  aminoglycosides  (AGs),  which  may
cause  hearing  loss.  Some  AGs  are  classiﬁed  as  more  vestibu-
lotoxic  (affecting  the  vestibular  system),  whereas  others  are
more  cochleotoxic  (affecting  the  cochlea).  Therefore,  the
monitoring  of  these  patients’  hearing  is  recommended  for
early  detection  of  signs,  even  asymptomatic  ones,  of  dete-
rioration  and  damage  to  the  auditory  system.8
Ototoxic  drugs  can  damage  the  organ  of  Corti  directly,
ﬁrst  degenerating  the  outer  hair  cells,  starting  with  the  spi-
rals  at  the  base  of  the  cochlea  and  spreading  toward  its  apex.
The  cell  degeneration  may  extend  to  the  inner  hair  cells,
starting  in  the  cochlea  apex,  if  exposure  to  the  ototoxic
agent  persists.9
Ototoxicity  has  played  an  important  role,  especially
in  younger  children,  since  it  is  generally  considered
irreversible  and  results  in  severe  future  harm.10 Audio-
metric  tests  that  assess  high  frequencies  are  especially
used  to  detect  ototoxicity-related  sensorineural  hearing
loss.11
High-frequency  audiometry  (HFA)  is  mentioned  in  the
international  literature  as  sensitive  for  the  early  detec-
tion  of  hearing  loss  caused  by  ototoxic  medications.
Although  there  is  no  criterion  for  result  interpretation,  many
researchers  have  stated  that  hearing  monitoring  is  essen-
tial  to  prevent  a  degeneration  process  from  occurring  in  the
basal  spiral  of  the  cochlea.12--15
HFA  is  considered  a  subjective  hearing  assessment,  car-
ried  out  in  a  soundproof  booth,  using  headphones  that
are  specially  calibrated  to  emit  high-pitched  sounds  of
8000--16,000  Hz.15 This  test  contributes  to  a  better  under-
standing  of  cochlear  lesion  at  higher  frequencies,  which
cannot  be  obtained  with  conventional  audiometry,  of  which
frequency  range  goes  only  up  to  8000  Hz.
Hearing  monitoring  should  allow  lesion  identiﬁcation
before  the  damage  reaches  speech  frequencies  and  thus
threaten  their  understanding.  According  to  previous  stud-
ies,  it  is  well  established  that  hearing  loss  caused  by  ototoxic
drugs  begins  at  the  base  of  the  cochlea,  affecting  primarily
the  higher  frequencies.16
HFA  seems  to  identify  asymptomatic  hearing  damage  in
CF  patients  and  may  contribute  to  the  early  detection  of
hearing  loss.17,18 The  search  for  scientiﬁc  evidence  in  this
context  becomes  necessary,  as  these  patients  usually  have
access  to  conventional  audiometry,  but  could  beneﬁt  even
further  from  the  hearing  evaluation  at  higher  frequencies.
The  objective  of  this  research  is  to  evaluate  the  accuracy  of
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he  HFA  in  identifying  hearing  loss  in  pediatric  patients  with
F.
ethods
 systematic  review  was  carried  out  in  the  PubMed,  MED-
INE,  Web  of  Science  and  LILACS  databases.  There  was  no
estriction  regarding  the  year  of  publication.  The  following
escriptors  from  DeCS  (Health  Sciences  Descriptors)  were
sed:  audiometry,  hearing  loss,  cystic  ﬁbrosis,  aminogly-
osides  and  abnormalities,  drug-induced,  as  well  as  their
orresponding  terms  in  Portuguese.
The  evaluation  of  the  titles  and  abstracts  identiﬁed  in
he  initial  search  was  carried  out  independently  by  two
esearchers,  strictly  following  the  inclusion  and  exclusion
riteria  previously  deﬁned  in  the  research  protocol.  Studies
ere  included  when  the  title,  subject  and/or  keywords  were
onsistent  with  the  purpose  of  this  study  carried  out  in  chil-
ren  and  adolescents  with  cystic  ﬁbrosis  receiving  treatment
ith  ototoxic  medication.  The  interventions  should  include
FA,  which  is  the  measurement  of  the  outcome  of  interest
hearing  thresholds  at  high  frequencies).  Articles  written  in
ortuguese,  Spanish  and  English  were  considered.
To  evaluate  the  methodological  quality  of  the  articles,  we
hose  to  use  the  GRADE  (Grades  of  recommendation,  assess-
ent,  development,  and  evaluation)  system.  This  system
rovides,  in  addition  to  criteria  for  the  degree  of  evi-
ence,  a deﬁnition  for  the  quality  of  evidence.  This  system
ims  to  be  clear  and  explicit,  considering  the  study  design,
erformance,  consistency,  as  well  as  direct  and  linear  direc-
ion  when  assessing  quality  of  evidence  for  each  important
utcome/consequence.19,20 The  quality  of  evidence  accord-
ng  to  the  GRADE  system  is  shown  as  follows21:
 High  (A):  Consistent,  with  evidence  from  randomized
controlled  trials  or  meta-analyses  without  signiﬁcant
limitations  or  with  exceptionally  strong  evidence  from
observational  studies.  It  is  very  unlikely  that  additional
research  will  change  the  conﬁdence  in  the  estimated
effects.
 Moderate  (B):  Evidence  from  randomized  controlled  trials
with  signiﬁcant  limitations  (inconsistent  results,  method-
ological  ﬂaws,  inaccuracies,  indirect  results).  Additional
research  is  likely  to  have  an  impact  on  the  conﬁdence  of
the  estimate  of  effect  and  may  change  this  estimate.
 Low  (C):  Evidence  from  at  least  one  important  result  of
observational  studies,  series  of  cases  or  randomized  con-
trolled  trials  with  serious  ﬂaws  or  indirect  evidence.  It
is  very  likely  that  further  research  will  have  a  signiﬁcant
impact  on  the  conﬁdence  of  the  effect  estimate  and  is
likely  to  change  the  estimate.
 Very  low  (C):  Any  effect  estimate  is  uncertain.
The  evidence  that  constitutes  systematic  reviews  are  not
irectly  indicated  as  recommendations,  but  constitute  tools
hat  support  the  ﬁnal  recommendations  of  guidelines.  The
RADE  system  considers  as  strong  the  recommendation  of diagnostic  test  when  the  beneﬁts  clearly  outweigh  the
isks  and  ‘‘burden  of  disease’’  or  vice  versa.  When  the  bene-
ts  are  limited,  showing  risks  and  ‘‘burden  of  disease’’,  the
RADE  system  classiﬁes  it  as  weak  recommendation.22
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Studies included in the
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tigure  1  Flowchart  of  the  search  and  selection  process  of  stu
reated with  ototoxic  medications.
esults
uring  the  search  process,  carried  out  from  January  to
ovember  2015,  512  publications  were  identiﬁed  (250  in
ubMed,  118  in  MedLine,  142  in  Web  of  Science  and  2  in
ILACS).  After  the  exclusion  of  repeated  articles  in  the  sur-
eyed  databases,  a  total  of  224  articles  were  obtained.  After
eading  the  titles  and  abstracts,  211  articles  were  excluded,
s  they  did  not  assess  the  outcome  or  exposure  of  interest.
he  remaining  13  publications  were  reviewed  by  reading  and
ssessing  the  full  text.  At  this  stage,  four  publications  were
xcluded,  as  they  did  not  assess  the  outcome  of  interest.
hus,  the  search  strategy  identiﬁed  nine  articles  that  met
he  inclusion  criteria  for  this  review  according  to  the  study
election  ﬂowchart  (Fig.  1).  The  nine  publications  selected
fter  the  search  strategy  are  shown  in  Table  1  and  the  quali-
cation  of  evidence  according  to  the  GRADE  system  is  shown
n  Table  2.
iscussion
ll  studies  included  in  this  review  report  hearing  loss
n  groups  of  CF  patients  receiving  treatment  with  oto-
oxic  drugs.  However,  statistically  signiﬁcant  results  were
bserved  in  ﬁve  of  these  studies  that  performed  HFA  in
atients  with  cystic  ﬁbrosis  treated  with  AGs.23,24,18,25,26
In  the  other  four  studies  of  this  review,  the  authors
bserved  that  the  risk  for  cochleotoxicity  in  CF  is  relatively
ow,  with  no  signiﬁcant  difference  between  patient  and  con-
rol  groups.  These  studies  suggest  carrying  out  additional
esearch  that  may  include  the  cumulative  effect  of  drug
t
t
r
aon  auditory  thresholds  in  pediatric  patients  with  cystic  ﬁbrosis
se.27--29,14 These  less  signiﬁcant  results  seem  to  be  related
o  the  short-term  follow-up  of  patients  in  these  studies.
Regarding  the  applicability  of  HFA,  all  studies  recom-
end  its  use  for  auditory  monitoring  as  a  complementary
ssessment  to  pure  tone  audiometry  (PTA)  for  CF  patients.
A  systematic  review  carried  out  to  analyze  the  national
cientiﬁc  production  regarding  the  clinical  application  of
FA  and  its  use,  concluded  that  the  HFA  has  been  widely
sed  in  audiological  practice  for  the  early  identiﬁcation  of
earing  alterations,  in  the  auditory  monitoring  of  subjects
xposed  to  ototoxic  drugs  or  aggressive  agents  and  comple-
entary  diagnosis  when  assessing  special  populations,  as  in
he  case  of  patients  with  chronic  kidney  disease,  diabetes
nd  hearing  disorders.17
Part  of  the  studies  included  in  this  study  used  distortion-
roduct  otoacoustic  emissions  (DPOAE)  in  the  auditory
ssessment  of  these  patients,  showing  that  this  test  also
ontributed  to  the  diagnosis  of  ototoxicity  in  children  with
F.23,18,25,26,29 The  advantage  of  this  test  is  to  allow  hear-
ng  loss  detection  in  children  younger  than  4  years,  who
ormally  cannot  be  submitted  to  audiometry,  as  it  requires
atient  conditioning  methods  that  are  not  always  feasible.
s  for  the  limitation  of  DPOAE  use,  it  usually  only  detects
osses  of  less  than  45  dB  HL.
In  a study  that  monitored  the  hearing  of  patients  exposed
o  cisplatin,  13  individuals  were  evaluated  through  the  hear-
ng  threshold  testing  from  250  Hz  to  18  kHz,  in  addition
o  the  transient  otoacoustic  emissions  (TOAE)  and  distor-
ion  product  otoacoustic  emissions  (DPOAE).  It  was  observed
hat,  after  the  infusion  of  120  mg/m2 of  cisplatin,  the  audi-
ory  thresholds  became  worse  from  the  frequency  of  8  kHz,
ecorded  by  the  HFA.  The  overall  response  and  absolute
mplitude  at  frequencies  of  1,  2  and  3  kHz  of  TOAE  tend
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Table  1  Main  characteristics  of  the  studies.
Title/author/year Design  Sample  Intervention  Results Conclusion
Absence  of
Cochleotoxicity
measured  by
standard  and
high-frequency
pure  tone
audiometry  in  a
trial  of  once-  vs.
three  times-daily
tobramycin  in
cystic  ﬁbrosis
patients  (Mulheran
et  al.,  2006).
Experimental
study:  randomized
controlled  trial.
Web  of  Science,
PubMed  -- indexed
for  MedLine
244  patients  with
Cystic  Fibrosis  (CF)
were  included,  of
which  219  (125
children  and  94
adults)  underwent
audiometry.  Results
were  obtained  for
168  of  the  total
number  of  patients
who  completed
treatment.
Pure  tone  audiometry
was  performed
throughout  the
frequency  range  of
0.25--8  kHz.
High-frequency
audiometry  of
10--16  kHz.
Audiometric  tests
were  performed  at
the  beginning  of  the
treatment  with
tobramycin,  at  the
end  of  a  14-day
treatment,  and  6--8
weeks  later.
No  signiﬁcant  differences
were  detected  in  the
auditory  thresholds
between  treatment
regimens.  There  was  loss  of
hearing  thresholds  at  high
frequencies  in  both  groups
of  treatment  regimens.
No  cumulative
cochleotoxicity  risk  was
demonstrated  in  patients
with  CF  due  to  repeated
therapy  with
aminoglycosides,
requiring  a  better
characterization.
Aminoglycoside
antibiotics
cochleotoxicity in
pediatric  Cystic
Fibrosis  (CF)
patients  (Al-Malky
et  al.,  2011).
Observational
cohort  study:  Web
of  Science,
PubMed--indexed
for  MedLine
45  children  with
cystic  ﬁbrosis  (CF).
39/45  participants
had  received
aminoglycosides
(AGs),  through
intravenous  (IV)
route,  23  of  them
having  received  it
repeatedly  every  3
months.
Audiometric  tests  and
distortion-product
otoacoustic  emissions
(DPOAE)  were
performed  during
routine  visits  to  the
CF  outpatient  clinic
or  when  patients
were  hospitalized.
Participants  were
grouped  according  to
their  prior  history  of
AG exposure
intravenously.
In  the  high-exposure  group,
8 (21%)  had  clear  signs  of
ototoxicity;  thresholds  at
8--20  kHz  were  elevated  by
∼50  dB.  DPOAE  amplitudes
were  >10  dB  lower  in  f2
3.2--6.3  kHz.  The  remaining
31/39  (79%)  patients
exposed  to  treatment  with
AGs  maintained  normal
hearing  threshold.
A  signiﬁcant  number  of
children  with  CF  had
ototoxicity  due  to
repeated  courses  of
treatment  with  AGs
intravenously.  It  is
recommended  to
perform  auditory  tests  in
all CF  patients  with  high
exposure  to  AG.  The
occurrence  of  hearing
loss  (HL)  was  associated
with  high  exposure;
however,  high  exposure
only  resulted  in  HL  in  a
minority  of  patients.
Genetic  analysis  may
help  explain  the
dichotomy  found  in
response  to  AGs.
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Table  1  (Continued)
Title/author/year  Design  Sample  Intervention  Results  Conclusion
Aminoglycoside
ototoxicity  in  cystic
ﬁbrosis.  Evaluation
by  high-frequency
audiometry
(McRorie,  Bosso,
Randolph,  1989).
Observational
study:  paired
case-control.  Web
of  Science,
PubMed  --  indexed
for  MedLine.
22  patients  with
Cystic  Fibrosis  (CF)
treated  with
aminoglycosides
(AGs).  13  of  them
were  paired  and
compared  to  38
individuals  without
CF,  who  had  never
received  treatment
with  AGs.
Audiometric  tests
were  performed  to
measure  hearing
thresholds  of
250--20,000  Hz.
In  patients  with  CF  that
were  treated  with  AGs
(younger  than  20  years),
there  were  statistically
signiﬁcant  differences  in
frequencies  >  16  kHz.  CF
patients  who  were  treated
with  AG  older  than  20  years
had  elevated  thresholds  at
all  tested  frequencies.  CF
patients  who  were  not
treated  with  AG  did  not
differ  statistically.
The  high-frequency
audiometry  can  be  a
useful  measure  of  the
increase  in  hearing
thresholds  preceding  the
noticeable  loss  of
hearing  acuity  in  CF
patients  who  are  treated
with  long-term  AGs.
Assessment of
ultra-high
frequency
audiometry  use  in
patients  receiving
ototoxic  drugs
(Weigert  et  al.,
2013).
Observational,
cross-sectional
study  with
unpaired  control
group.  LILACS
69  individuals  aged
7--20  years  of  age.  35
patients  regularly
submitted  to  therapy
with  potentially
ototoxic  medication
that  were  part  of  the
study  group  (SG)  and
34 healthy  subjects
that  were  the  control
group  (CG).
Conventional
audiometry
(250--8000  Hz)  and
audiometry  at
ultra-high
frequencies
(9000--16,000  Hz)
were  performed.
There  was  one  altered  case
in the  conventional
audiometry  (2.9%)  and  6
altered  cases  in  the
audiometry  at  ultra-high
frequencies  (17.1%)
(p =  0.063).  The  SG  had
statistically  higher
thresholds  in  relation  to  the
CG  in  the  conventional
audiometry  at  the
frequencies  of  2  kHz  and
8  kHz  and,  in  the
audiometry  with  ultra-high
frequencies,  at  10  kHz
(p =  0.004)  and  16  kHz
(p <  0.001).
The  study  suggested  that
the  audiometry  in
ultra-high  frequencies  is
useful  for  hearing
monitoring  in  patients  at
risk for  ototoxicity.
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Table  1  (Continued)
Title/author/year Design  Sample  Intervention  Results Conclusion
Cumulative  and  acute
toxicity  of
repeated  high-dose
tobramycin
treatment  in  cystic
ﬁbrosis  (Pedersen
et al.,  1987).
Observational,
cross-sectional
study.  Web  of
Science,  PubMed
indexed  for
MedLine.
46  patients  with
Cystic  Fibrosis  (CF),
mean  age  of  15.7
years  and  chronic
bronchopulmonary
infection  by
Pseudomonas
aeruginosa.
Patients  were  studied
before  and  at  the  end
of a  two-week  course
of  treatment  with
tobramycin
(10--20  mg/kg  per
day)  to  discriminate
between  acute  and
chronic  toxicity  using
audiometry  and
electronystagmogra-
phy
tests.
Two  patients  (5%)  had
hearing  loss  at  high
frequency  (above  8  kHz),
but only  one  related  to
tobramycin.  No  chronic
vestibular  toxicity  was
observed.  After  2  weeks  of
treatment,  32%  had  a
slightly  reduced  hearing
threshold  (15--30  dB)  at  two
or more  high  frequencies
and  28%  had  a  decrease  in
the superior  vestibular
response  at  25%  of  the
initial  value,  but  remained
within  normal  limits.
The  acute  and  chronic
toxicity  during
treatment  with  high
doses  of  tobramycin  in
CF  patients  seems  to  be
very  mild.
Hearing loss  in  cystic
ﬁbrosis  (Martins
et al.,  2010).
Observational,
cross-sectional,
descriptive  study.
Web  of  Science,
PubMed  indexed
for  MedLine.
120  patients  with
Cystic  Fibrosis  (CF)
aged  5  months  to  18
years.
The  study  was  carried
out  through
questionnaires,
audiometric  testing
and analysis  of
distortion-product
otoacoustic  emissions
(DPOAE).  The
evaluation  of  prior
use  of  aminoglycoside
antibiotics  (AGs)  was
performed  by
collecting  data  from
medical  records.
Audiometric  tests  showed  a
4--11%  prevalence  of
sensorineural  hearing  loss.
There  was  no  statistically
signiﬁcant  association
between  the  use  of  AGs  and
hearing  loss  (p  =  0.48).
Analysis  of  audiometric
tests  and  DPOAE  showed
that  there  was  a  high
prevalence  of  hearing
loss,  which  makes  CF
patients  a  group  of  high
risk that  requires
periodic  hearing
assessment.  The
comparison  of  the  groups
with  and  without  use  of
AGs  showed  no
statistically  signiﬁcant
difference,  suggesting
that  the  use  of  AGs  is  not
the  only  causal  factor  for
hearing  loss  in  CF.
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Table  1  (Continued)
Title/author/year  Design  Sample  Intervention  Results  Conclusion
High-frequency
audiometry  reveals
high  prevalence  of
aminoglycoside
ototoxicity  in
children  with  cystic
ﬁbrosis  (Al-Malky
et al.,  2015).
Observational,
cross-sectional,
prospective  study.
Web  of  Science,
PubMed  --  in
process.
70  children  with
Cystic  Fibrosis  (CF).
Mean  age  of  10.7
years.
Hearing  assessment
was  performed  in
children  with  CF  using
standard  pure  tone
audiometry  (PTA)  and
high  frequency
audiometry  (HFA),  as
well  as
distortion-product
otoacoustic  emissions
(DPOAE).
Of  the  63  children  who
received  intravenous  (IV)
AGs,  15  (24%)  had
ototoxicity  detected  by  HFA
and  DPOAE.  PTA  detected
ototoxicity  in  5  children
(only  at  the  frequency  of
8 kHz,  with  hearing  loss
>20 dB  HL)  and  13  children
with  some  non-signiﬁcant
change.  A  hearing  loss  of
25--85  dB  HL  at  all  high
frequencies  and  a
signiﬁcant  decrease  in
DPOAE  amplitude  at
frequencies  of  4--8  kHz  were
detected.  There  was  a
statistically  signiﬁcant
difference  (p  <  0.05)  in  the
hearing  threshold  between
the groups  at  high
frequencies  (8--16  kHz).
Children  with  CF  who
received  at  least  10  AG
courses  through  IV  route
had  a  higher  risk  of
ototoxicity.  HFA
identiﬁed  2  children
with  ototoxicity  more
than  PTA.  Depending  on
the  available  facilities,
HFA  must  be  the  test  of
choice  for  the  detection
of  ototoxicity  in  children
with  CF  who  received
treatment  with  AGs.
High frequency
hearing  thresholds
and  product
distortion
otoacoustic
emissions  in  cystic
ﬁbrosis  patients
(Geyer,  Barreto,
Weigert,  Teixeira,
2015).
Observational
cross-sectional,
retrospective  and
prospective  study
with  a  control
group.
MedLine
PubMed-in
process.
Children  and
adolescents  from
adult  and  pediatric
Cystic  Fibrosis  (CF)
outpatient  clinics.
The  sample  consisted
of 75  individuals,  39
in the  Study  Group
(SG)  and  36  in  the
control  group  (CG).
Existing  data  were
used,  from  a
database  created
earlier.  Further  tests
were  added  to  this
database,  by
conducting  pure  tone
audiometry  (PTA),
High-Frequency
Audiometry  (HFA)  and
distortion  product
otoacoustic  emissions
(DPOAE)  in  more
patients  from  the
Cystic  Fibrosis
Outpatient  Clinic  (SG)
and  Control  Group
(CG).
The  SG  had  signiﬁcantly
higher  thresholds  at  250,
1000,  8000,  9000,  10,000,
12,500  and  16,000  Hz;
(p =  0.004).
There  was  a  signiﬁcant
association  between
changes  in  hearing
thresholds  in  the  HFA  with
the  number  of  courses  of
aminoglycosides  (AGs)  that
were  carried  out  (p  =  0.005).
83%  of  patients  who  had
more  than  10  courses  of  AGs
had  hearing  loss  in  the  HFA.
A  signiﬁcant  number  of
CF  patients  who
received  repeated  AGs
courses  showed  changes
in  the  HFA  and  DPOAE.
Receiving  10  or  more  AG
courses  was  associated
with  changes  in  the  HFA.
A
RTICLE IN PRESS
+M
odel
H
earing
 thresholds
 at
 high
 frequency
 in
 patients
 w
ith
 cystic
 ﬁbrosis
 
9
Table  1  (Continued)
Title/author/year Design  Sample  Intervention  Results Conclusion
Occurrence  and  risk
of  cochleotoxicity
in cystic  ﬁbrosis
patients  receiving
repeated  high-dose
aminoglycoside
therapy  (Mulheran
et  al.,  2001).
Observational
cross-sectional,
retrospective
study  with  a
control  group.
Web  of  Science,
PubMed  -- indexed
for  MedLine.
70  patients  with  CF
subdivided  into
groups;  27  pediatric
patients  (10--18
years)  and  43  adults
(19--37  years).  Results
were  compared  with
the  results  of  91
individuals  from  the
control  group.
Standard  pure  tone
audiometry
(0.25--8  kHz)  and
high-frequency
audiometry
(10--16  kHz)  were
performed.
Of  70  patients  with  CF,  12
(one  pediatric  patient)  had
hearing  loss  considered  to
be  caused  by  repeated
exposure  to
aminoglycosides  (AGs).
There  was  a  nonlinear
association  between  the
therapy  courses  received
and  the  incidence  of
hearing  loss.  Loss  severity
does  not  seem  to  be
associated  with  the  number
of  courses  received.
Preliminary  risk  estimates
of  hearing  loss  per  AG
course  were  less  than  2%.
After  comparison  with
previous  clinical  studies
and  experimental  work,
these  ﬁndings  suggest
that  the  incidence  of
cochleotoxicity  in  CF
patients  is  considerably
lower  than  expected,
suggesting  that  the  CF
condition  can  confer
protection  against
cochleotoxicity.
ARTICLE IN PRESS+Model
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Table  2  GRADE  System  for  quality  of  evidence.
Author/year/design  Class  A  Class  B  Class  C
Geyer  LB,  Menna  Barreto  SS,  Weigert  LL,  Teixeira  AR,  2015  (Observational,  cross-sectional
study,  with  paired  control  group).
X
Al-Malky  G  et  al.,  2015  (Observational,  cross-sectional  study).  X
Weigert LL,  et  al.,  2013  (Observational,  cross-sectional  study,  with  non-paired  control
group).
X
Al-Malky G,  et  al.,  2011  (Cohort  study).  X
Mulheran M,  et  al.,  2006  (Randomized  clinical  trial).  X
Martins LMN,  et  al.,  2010  (Observational,  cross-sectional  study)  X
Mulheran M,  et  al.,  2001  (Observational,  cross-sectional  study,  with  paired  control  group). X
McRorie TI,  Bosso  J,  Randolph  L,  1989  (Observational,  paired  case-control  study). X
Pedersen  SS,  et  al.,  1987  (Observational,  cross-sectional  study). X
 or very low.
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Table  3  AG  antibiotic  administration  route  observed  in  the
studies.
Drug  administration  route  Number  of
studies
Intravenous  7
Inhaled  0  (zero)
Both 1
No information  on  drug 1
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o  remain  present  until  the  end  of  treatment,  but  the  same
oes  not  occur  with  the  frequency  of  4  kHz.  The  authors  con-
luded  that  the  HFA  was  the  most  effective  method  for  early
etection  of  cisplatin  ototoxicity.30
Four  studies  included  in  this  review  identiﬁed  more
atients  with  ototoxicity  signs  through  HFA  when  compared
o  conventional  audiometry.23,24,18,28 These  studies  suggest
hat  HFA  should  be  performed  for  ototoxicity  detection  in
nfants  with  CF  who  received  treatment  with  AGs.
In  the  studies  by  Mulheran  et  al.  (2001)14 and  Mulheran
t  al.  (2006)27,  the  decrease  in  the  thresholds  at  high
requencies  is  observed  in  both  the  control  group  and  in
atients  with  CF.  The  authors  suggested  that  CF  can  act  as
 protective  factor  against  cochleotoxicity  because  of  the
aster  renal  elimination  of  AGS,  reporting  that  the  defect
hat  causes  decreased  permeability  to  chloride  can  dam-
ge  the  transport  of  AGs  into  the  outer  and  inner  hair
ells  of  the  cochlea.  Other  factors  related  to  hearing  loss,
uch  as  prematurity  and  history  of  intrauterine  infection,
n  addition  to  AGs  use,  could  contribute  to  a  higher  preva-
ence  of  hearing  loss  in  the  group  that  did  not  received
Gs.
Two  studies  in  this  review  suggested  that  the  use  of  AGs  is
ot  the  only  causal  factor  for  hearing  loss  in  CF.23,29 Accord-
ng  to  Al-Malky  et  al.  (2011)23 the  occurrence  of  hearing
oss  has  been  associated  with  high  exposure  to  AGs;  how-
ver,  the  high  exposure  resulted  in  hearing  loss  in  a  minority
f  patients.  According  to  the  authors  of  this  study,  genetic
nalysis  may  help  explain  the  dichotomy  found  in  response
o  GAs.
Conrad  et  al.  (2008)31 veriﬁed  that  genetic  predisposition
hrough  mitochondrial  mutation  (A15555G)  makes  patients
ore  susceptible  to  hearing  loss  caused  by  AGs,  even  with
maller  doses  of  the  drug.  New  prospective  studies  may  help
o  elucidate  the  cause  of  hearing  loss  in  CF.
A  systematic  review  that  sought  to  evaluate  the  role  of
outine  hearing  screening  for  sensorineural  hearing  loss  in
hildren  with  CF  treated  with  AGs  showed  that  the  most  fre-
uently  used  test  in  the  studies  was  the  HFA  (6/12),  followed
y  DPOAE  (4/12),  and  only  one  study  included  the  TOAE
1/12)  and  auditory  brainstem  response  (1/12).32 Other
tudies  using  HFA  for  auditory  monitoring  in  patients  dur-
ng  treatment  with  ototoxic  drugs  (chemotherapy  or  renal
unction  conservative  agents),  reinforce  the  importance  of
a
i
o
tadministration  route
he  test’s  clinical  applicability  to  prevent  permanent  hearing
oss.30,33,34
The  study  by  Martins  et  al.  (2010)29 recorded  hearing  loss
n  4%  of  the  sample  when  considering  the  mean  tritone  fre-
uencies  of  500,  1000  and  2000  Hz.  When  using  other  criteria
o  deﬁne  hearing  loss,  which  considered  an  increase  in  the
uditory  threshold  in  two  or  more  frequencies,  including  the
igh  ones,  hearing  loss  higher  than  25  dB  HL  was  found  in  11%
f  the  patients.  Since  it  is  known  that  AGs  cause  hearing
oss  initially  at  high  frequencies,  which  are  disregarded  in
he  ﬁrst  criterion,  it  reinforces  the  importance  of  auditory
onitoring  by  HFA.  Thus,  even  if  patients  have  no  clinically
igniﬁcant  hearing  loss,  they  may  beneﬁt  from  the  monitor-
ng  that  includes  high  frequencies,  when  a  new  treatment
ith  ototoxic  medication  is  started.  The  variability  of  the
riteria  used  reinforces  the  idea  that  hearing  loss  can  be
nderdetected  when  the  conventional  hearing  loss  criteria
re  used.35
The  AG  antibiotic  route  of  administration  was  observed
n  the  studies  of  this  review,  as  shown  in  the  following  table
Table  3).
The  pharmacokinetics  of  all  AGs  is  quite  similar.  Due
o  their  polar  nature,  they  are  poorly  absorbed  from  the
astrointestinal  tract,  with  less  than  1%  of  the  dose  being
bsorbed  after  oral  or  rectal  administration.  The  main  route
f  administration  is  therefore  parenteral,  with  the  drug
eaching  maximum  plasma  concentration  30--90  min  after
n  intramuscular  injection  and  30  min  after  an  intravenous
njection.  Antibiotic  therapy  is  indicated  for  the  treatment
f  disease  exacerbation  and  for  preventive  treatment  aiming
o  suppress  the  bacterial  load.36
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Hearing  thresholds  at  high  frequency  in  patients  with  cystic
The  most  recent  evidence  has  justiﬁed  the  use  of  inhaled
antibiotic  therapy  in  patients  with  chronic  infection  from
Pseudomonas  aeruginosa, as  maintenance  or  chronic  sup-
pression  treatment,  especially  in  CF  patients.  Although  the
use  of  inhaled  tobramycin  is  based  on  randomized  controlled
trials,37 because  of  its  high  cost,  its  use  has  been  reserved
for  patients  who  did  not  tolerate  or  did  not  respond  to  other
antibiotics.38,39
Among  the  three  studies  that  evaluated  and  compared
hearing  in  adults  and  children  with  CF  receiving  AGs,24,27,14
two  found  more  hearing  alterations  in  adult  patients.24,14
McRorie,  Bosso  and  Randolph  (1989)24 found  signiﬁcant  dif-
ferences  in  frequencies  above  16,000  Hz  in  patients  younger
than  20  years  and  high  thresholds  at  all  frequencies  tested
in  patients  older  than  20  years.  In  the  study  by  Mulheran
(2001),14 which  evaluated  70  CF  patients  using  AGs,  27  chil-
dren  and  43  adults,  it  was  found  that  only  one  of  the  children
had  hearing  loss  attributed  to  the  use  of  AGs.  When  the
results  in  adults  were  analyzed,  it  was  found  that  11  patients
showed  hearing  loss  attributed  to  AGs.  The  more  signiﬁcant
results  in  the  group  of  adult  patients  may  be  associated  with
long-term  use  of  ototoxic  medication,  suggesting  a  cumula-
tive  risk.
The  study  carried  out  by  Mulheran  et  al.  (2006)27 suggests
strong  scientiﬁc  evidence,  as  it  is  a  randomized  controlled
trial.  This  study  was  carried  out  with  125  children  and  94
adults  with  CF,  aiming  to  investigate  the  cumulative  risk  of
ototoxic  drug  use.  It  compared  a  group  of  patients  under-
going  treatment  with  a  daily  dose  of  tobramycin  to  a  group
treated  with  three  doses  of  the  drug.  The  audiometry  was
performed  at  the  start  of  the  treatment,  at  the  end  of  a  14-
day  treatment  and  6--8  weeks  after  treatment  completion.
The  hearing  thresholds  in  both  treatment  groups  decreased
between  25  and  75  dB  HL  at  the  frequencies  of  10--16  kHz.
Therefore,  the  loss  of  hearing  threshold  in  these  patients
was  found  with  both  lower  and  higher  doses  of  ototoxic  med-
ication.  Hearing  loss  was  identiﬁed  by  HFA  in  these  patients,
but  it  was  not  possible  to  verify  differences  between  the
treatment  doses,  as  the  study  intended.
However,  there  is  strong  evidence  that  HFA  can  identify
early  signs  of  hearing  loss  or  progressive  decreases  in  audi-
tory  thresholds,  even  if  they  are  not  exclusively  related  to
the  use  of  ototoxic  drugs.
Conclusion
High-frequency  audiometry  has  been  researched  and  used  as
a  diagnostic  and  monitoring  tool  for  hearing  loss  in  patients
with  cystic  ﬁbrosis.
This  review  identiﬁed  the  occurrence  of  hearing  loss  at
high  frequencies  in  patients  with  cystic  ﬁbrosis  who  did  not
have  hearing  complaints.
It  is  postulated  that  high-frequency  audiometry  may  be
an  early  diagnostic  method  to  be  recommended  for  hearing
investigation  in  patients  at  risk  of  ototoxicity.Conﬂicts of interest
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